Evaluating the IDH, ATRX and P53 Immunohistochemistry in Glial Tumours: A Tertiary Centre Experience
DOI:
https://doi.org/10.21276/apalm.3936Keywords:
glial tumours, grade, molecular, WHOAbstract
Background: Adult glial tumours continue to be a challenge for medicine for its poor prognostic effects. Due to its invasiveness and resistance to therapy it causes a lot of mortality and morbidity. The recent 5th edition WHO has changed the understanding of the spectrum of glial tumours through cytogenetic advancement. The diagnostic approach to spectrum of glial tumours has been changed due to the inclusion of molecular genetics. Molecular alterations are now the most important factor for diagnosis, classification and prognosis.
Aims & Objectives: In the present study we aim to study spectrum of adult glial tumours along with immunohistochemical (IHC) study with IDH1, ATRX and p53 in a tertiary care centre. In this study we compared the histopathological features of these tumours with IHC expression to ascertain any existing correlation between two. This study also looks into any existing relation between the IHC expression and biology of the tumour.
Material & Methods: This prospective study was done on 42 patients over a period of one and a half year. Patients with clinical symptoms of brain tumour were selected. The necessary neurosurgical procedure was done followed by histopathological diagnosis of the resected specimen. IHC study with IDH1, ATRX and p53 was done on the glial tumour tissue. All the data including clinic-radiological features were collected and statistical analysis was done using software.
Results: Among 42 cases 66.67% of male and 33.33% female. Majority of the cases were glioblastoma. Most of the patients were affected in 4th decade of life. IDH1 expression was inversely related with WHO grade (p=.056) indicating that with increasing grade preponderance of IDH wild type increase and IDH1 mutant decreased. Significant correlation was found between histopathological subtype and IDH1 expression (p=0.000). ATRX expression showed no significant correlation with WHO grade (0.373) and with histopathological subtype. p53 expression also showed no correlation with WHO grade and histopathological subtype.
Conclusion: This study was an institution-based study on 42 adult glial tumours. It was carried out during one-and-a-half-year period of January of 2021 to July of 2022. This study has showed that immunohistochemistry (IHC) could be used as a partial surrogate to genetic analysis in low resource setting. However, for more extensive analysis genetic testing is essential. IDH1 IHC in this study corroborated well with histological grade of adult gliomas.
References
1. Sofronie MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119:7–35.
2. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet 2018 392:432–46.
3. Alfonso JCL, Talkenberger K, Seifert M, Klink B, Hawkins-Daarud A et al. The biology and mathematical modelling of glioma invasion: a review. J R Soc Interface 2017 14:20170490.
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
5. Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent M, Wick W et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6:39–51.
6. Bovenberg MSS, Degeling MH, Tannous BA. Cell-based immunotherapy against gliomas: from bench to bedside. Mol Ther 2013; 21:1297–305.
7. Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med 2014; 6:1359–370.
8. Eyüpoglu IY, Buchfelder M, Savaskan NE. Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol. 2013; 9:141–51.
9. Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4):e13062. doi:10.1111/bpa.13062
10. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumours diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16 Suppl 4:iv1–iv63.
11. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A, et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873.
12. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS tumours in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403-413. doi:10.1215/15228517-2008-097.
13. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumours: current concepts and review of the literature. Neuro Oncol. 2002;4(4):278-299. doi:10.1093/neuonc/4.4.278.
14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clinical Cancer Research. 2009 Oct 1;15(19):6002-7.
15. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. Journal of Neuropathology & Experimental Neurology. 2005 Jun 1;64(6):479-89.
16. David N, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumours of the central nervous system: a summary. Acta Neuropathol 2016; 131:803-820.
17. A supratentorial primitive neuroectodermal tumor presenting with intracranial hemorrhage in a 42-year-old man: a case report and review of the literature. J Med Case Rep., 7 (2013), pp. 1-6.
18. Song X, Andrew Allen R, Terence Dunn S, Fung KM, Farmer P, Gandhi S, Ranjan T, Demopoulos A, Symons M, Schulder M, Li JY. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 2011; 4:651-660.
19. Perry A, Miller CR, Gujrati M, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009;19(1):81–90. doi:10.1111/j.1750-3639.2008.00167.x.
20. Kumagai M, Takata S, Watanabe T, Shioya A, Han J, Shimasaki M, et al. Glioblastoma/high-grade glioma with a primitive neuronal component including rhabdoid differentiation that was difficult to diagnose: a case report. Pathol Res Pract. 2023;251:154817.
21. Enomoto T, Aoki M, Hamasaki M, et al. Midline glioma in adults: clinicopathological, genetic, and epigenetic analysis. Neurol Med Chir (Tokyo). 2020;60(3):136-146. doi:10.2176/nmc.oa.2019-0168.
22. Gerstner ER, Pajtler KW. Ependymoma. Semin Neurol. 2018;38(1):104-111. doi:10.1055/s-0038-1636503.
23. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG. Descriptive epidemiology of primary brain and CNS tumours: results from the Central Brain Tumour Registry of the United States, 1990-1994. Neuro-oncol. 1999;1:14-25.
24. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer. 2011;11:325. doi:10.1186/1471-2407-11-325.
25. Hjalmars U, Kulldorff M, Wahlqvist Y, Lannering B. Increased incidence rates but no space–time clustering of childhood astrocytoma in Sweden, 1973–1992: a population-based study of pediatric brain tumours. Cancer. 1999 May 1;85(9):2077.
26. Soffietti R, Baumert BG, Bello L, Von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M. Guidelines on management of low-grade gliomas: report of an EFNS–EANO Task Force. European Journal of Neurology. 2010 Sep;17(9):1124-33.
27. Mattos JP, Marenco HA, Campos JM, et al. Cerebellar glioblastoma multiforme in an adult. Arq Neuropsiquiatr. 2006;64(1):132-135. doi:10.1590/s0004-282x2006000100028.
28. Malla S, Bavikar R, Gore C, Chugh A, Gurwale S. Histopathological spectrum of gliomas and its immunohistochemical correlation in a tertiary care setup. Cureus. 2024 Jul 21;16(7):e65036. doi:10.7759/cureus.65036.
29. Majhi S, Choudhuri S, Ray R, Ghosh S. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Journal of Contemporary Clinical Practice, 2025;11(5):603-609.
30. Lovejoy CA, Li W, Reisenweber S, Thongthip S, Bruno J, de Lange T, De S, Petrini JH, Sung PA, Jasin M, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8:e1002772.
31. Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, et al. Molecular testing of brain tumour. J Pathol Transl Med 2017; 51:205–23.
32. Sarma S, Khonglah Y, Mishra J, Kakati A, Phukan P. Gliomas - an experience based on molecular markers. J Family Med Prim Care 2021; 10:1341-6.
33. Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun 2016; 4:60.
34. Hariharan S, Whitfield BT, Pirozzi CJ, et al. Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas. Nat Commun 15, 730 (2024). https://doi.org/10.1038/s41467-024-44932-w.
35. Liu J, Zhang X, Yan X, Sun ME, Fan Y, Huang Y. Significance of TERT and ATRX mutations in glioma. Oncol Lett 2019; 17:95–102.
36. Pollack IF, Finkelstein SD, Woods J, et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420-427.
37. Pardo FS, Hsu DW, Zeheb R, Efird JT, Okunieff PG, Malkin DM. Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. British Journal of Cancer. 2004 Nov;91(9):1678.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Shivam Chakraborty, Chhanda Das, Shahid Iftekhar Sadique, Mamata Guha Mallick Sinha
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
